Effects of isoniazid on ultrastructure of Mycobacterium aurum and Mycobacterium tuberculosis and on production of secreted proteins.
Isoniazid (INH), one of the most effective antimycobacterial drugs, specifically inhibits, at an early stage of its action, the biosynthesis of mycolic acids, specific mycobacterial lipids which play a central role in the cell envelope architecture of mycobacteria. In the present study, the consequences of the action of INH on the cell morphology of Mycobacterium tuberculosis and Mycobacterium aurum were examined. Electron microscopy was used to observe bacilli which were previously treated with either subinhibitory concentrations of INH or the MIC of the drug, leading to a decrease of 20 to 35% (by weight) of their mycolic acid contents. The earlier effect of INH on the ultrastructure of mycobacteria, as revealed by negative staining of bacilli, was the alteration of the bacterial poles; this event was observed prior to the bacteriostatic action of the drug and was accompanied by a release of material from the poles into the extracellular medium. In a later stage of the drug's action, cell deformation occurred and more extracellular material was seen. The material released following the action of the drug on susceptible mycobacterial cells was identified as being almost exclusively composed of proteins. Labeling of amino acids with 35S prior to and during the action of INH on M. aurum and subsequent analysis of the labeled proteins led to the conclusion that they consisted of secreted proteins which were up to 20-fold oversecreted in the presence of the drug. Competitive enzyme-linked immunosorbent assay with the secreted 45/47-kDa antigen complex of M. tuberculosis demonstrated up to 20-fold oversecretion of these proteins. Taken together, the production of oversecreted proteins following the decrease of the cell envelope mycolate content by INH strongly suggests that mycolic acids may act as a barrier in the export of proteins secreted by mycobacteria.
Institut de Pharmacologie et de Biologie Structurale, Toulouse, France.
F
F
Bardou
A
A
Quémard
M A
MA
Dupont
C
C
Horn
G
G
Marchal
M
M
Daffé
D000995:Antitubercular Agents / Q000494:pharmacology*; D001426:Bacterial Proteins / Q000096:biosynthesis*; D015153:Blotting, Western; D002855:Chromatography, Thin Layer; D004591:Electrophoresis, Polyacrylamide Gel; D004797:Enzyme-Linked Immunosorbent Assay; D006868:Hydrolysis; D007521:Isocitrate Dehydrogenase / Q000378:metabolism; D007538:Isoniazid / Q000494:pharmacology*; D008854:Microscopy, Electron; D009161:Mycobacterium / Q000187:drug effects* / Q000378:metabolism* / Q000648:ultrastructure; D009169:Mycobacterium tuberculosis / Q000187:drug effects* / Q000378:metabolism* / Q000648:ultrastructure; D009171:Mycolic Acids / Q000378:metabolism; D013462:Sulfur Radioisotopes
D000995:Antitubercular Agents; D001426:Bacterial Proteins; D009171:Mycolic Acids; D013462:Sulfur Radioisotopes; D007521:Isocitrate Dehydrogenase; D007538:Isoniazid